DAT 2645
Alternative Names: DAT-2645Latest Information Update: 04 Dec 2024
Price :
$50 *
At a glance
- Originator Danatlas Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Poly ADP ribose glycohydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 27 Sep 2024 Preclinical trials in Solid tumours in China (PO), prior to September 2024 (NCT06614751)
- 27 Sep 2024 Danatlas Pharmaceuticals plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease) in China (PO), in November 2024 (NCT06614751)